What were the clinical trial results?

Two Phase 3 trials showed substantial weight loss, prompting the company to prepare regulatory applications.

When will retatrutide be available?

Eli Lilly has not announced a specific timeline but is preparing to submit applications soon.

How does retatrutide compare to existing obesity drugs?

Retatrutide is a triple agonist that may offer greater weight loss compared to single or dual receptor drugs like Wegovy and Mounjaro.

Eli Lilly Prepares Retatrutide Applications After Positive Phase 3 Data

Eli Lilly is preparing to submit regulatory applications for its next-generation obesity drug retatrutide, following positive data from two Phase 3 trials demonstrating substantial weight loss.

July 23, 2026

1 min read

Source: The Wall Street Journal

Eli Lilly (NYSE: LLY) is preparing regulatory applications for its next-generation obesity drug, retatrutide, after positive data from two Phase 3 trials showed substantial weight loss results.

The Product

Retatrutide is an investigational triple agonist (GLP-1/GIP/Glucagon) administered once weekly via injection. It aims to achieve greater weight loss compared to current drugs like Mounjaro (tirzepatide).

Pricing and Availability

Eli Lilly has not yet disclosed pricing or a timeline for submission. The company is expected to file applications with the FDA and other regulatory bodies soon.

Competition

Retatrutide competes with existing obesity drugs such as Wegovy (Novo Nordisk) and Mounjaro. Other candidates in development include AMG 133 (Amgen).

Potential Impact on the Company

If approved, retatrutide could strengthen Eli Lilly's position in the growing obesity market, which is estimated to be worth tens of billions of dollars.

Frequently Asked Questions

Retatrutide is an experimental obesity drug from Eli Lilly that targets three hormone receptors (GLP-1, GIP, and glucagon) to promote weight loss.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.